Characterization of a Portable Solid-State Breath Acetone Testing Device for Real-Time Ketosis Status

NCT ID: NCT04130724

Last Updated: 2019-12-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

21 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-10-16

Study Completion Date

2019-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary purpose of this study is to characterize the performance and utility of a novel breath acetone meter developed by Readout, Inc.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ketogenic Dieting Ketosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ketogenic diet

Subjects consuming either a ketogenic (\<30g carbohydrate per day) or a low-carb (\<100g carbohydrate per day) diet.

Blood ketone testing

Intervention Type DIAGNOSTIC_TEST

Ketone testing will be done using a blood beta-hydroxybutyrate (BHB) test at least five (5) times per day.

Breath ketone testing

Intervention Type DIAGNOSTIC_TEST

Ketone testing will be done using a breath acetone (BrAce) test at least five (5) times per day.

High-carbohydrate diet

Subjects consuming a high carbohydrate (\>100g carbohydrate per day) diet.

Blood ketone testing

Intervention Type DIAGNOSTIC_TEST

Ketone testing will be done using a blood beta-hydroxybutyrate (BHB) test at least five (5) times per day.

Breath ketone testing

Intervention Type DIAGNOSTIC_TEST

Ketone testing will be done using a breath acetone (BrAce) test at least five (5) times per day.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood ketone testing

Ketone testing will be done using a blood beta-hydroxybutyrate (BHB) test at least five (5) times per day.

Intervention Type DIAGNOSTIC_TEST

Breath ketone testing

Ketone testing will be done using a breath acetone (BrAce) test at least five (5) times per day.

Intervention Type DIAGNOSTIC_TEST

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Blood ketone testing using the Abbott Precision Xtra meter. Breath ketone testing using the Readout breath acetone device.

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ketogenic diet cohort: currently following a ketogenic or low-carbohydrate diet defined as less than 30 grams per day (ketogenic) or less than 100 grams per day (low-carbohydrate) as estimated by the individual. Subjects must have been following the diet before the beginning of the study period and must continue with the diet throughout the duration of the trial.
* High-carbohydrate diet cohort: currently following a diet that does not restrict dietary carbohydrate. Carbohydrate consumption should be greater than 100 grams per day as estimated by the individual. Subjects must have been following the diet before the study period and must continue with the diet throughout the duration of the trial.

Exclusion Criteria

* Type-1 diabetes
* Insulin-dependent type-2 diabetes
* History of diabetic ketoacidosis
* Currently taking Warfarin or other blood thinners
* Currently taking a sodium-glucose cotransporter-2 (SGLT2) inhibitor
* Currently taking Disulfiram
* Unwilling to maintain their diet during the study period
* Unwilling to test blood and breath ketones five times per day
* Non-English speaking
* Persons who are unable or unwilling to follow the study protocol or who, for any reason, the research team considers not an appropriate candidate for this study, including non-compliance with screening appointments or study visits.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Readout, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

James McCarter, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Readout, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Center for Emerging Technologies

St Louis, Missouri, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Hallberg SJ, McKenzie AL, Williams PT, Bhanpuri NH, Peters AL, Campbell WW, Hazbun TL, Volk BM, McCarter JP, Phinney SD, Volek JS. Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at 1 Year: An Open-Label, Non-Randomized, Controlled Study. Diabetes Ther. 2018 Apr;9(2):583-612. doi: 10.1007/s13300-018-0373-9. Epub 2018 Feb 7.

Reference Type BACKGROUND
PMID: 29417495 (View on PubMed)

Bhanpuri NH, Hallberg SJ, Williams PT, McKenzie AL, Ballard KD, Campbell WW, McCarter JP, Phinney SD, Volek JS. Cardiovascular disease risk factor responses to a type 2 diabetes care model including nutritional ketosis induced by sustained carbohydrate restriction at 1 year: an open label, non-randomized, controlled study. Cardiovasc Diabetol. 2018 May 1;17(1):56. doi: 10.1186/s12933-018-0698-8.

Reference Type BACKGROUND
PMID: 29712560 (View on PubMed)

Evert AB, Dennison M, Gardner CD, Garvey WT, Lau KHK, MacLeod J, Mitri J, Pereira RF, Rawlings K, Robinson S, Saslow L, Uelmen S, Urbanski PB, Yancy WS Jr. Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report. Diabetes Care. 2019 May;42(5):731-754. doi: 10.2337/dci19-0014. Epub 2019 Apr 18. No abstract available.

Reference Type BACKGROUND
PMID: 31000505 (View on PubMed)

Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 Feb 7;346(6):393-403. doi: 10.1056/NEJMoa012512.

Reference Type BACKGROUND
PMID: 11832527 (View on PubMed)

Van Gaal L, Scheen A. Weight management in type 2 diabetes: current and emerging approaches to treatment. Diabetes Care. 2015 Jun;38(6):1161-72. doi: 10.2337/dc14-1630.

Reference Type BACKGROUND
PMID: 25998297 (View on PubMed)

Boden G, Sargrad K, Homko C, Mozzoli M, Stein TP. Effect of a low-carbohydrate diet on appetite, blood glucose levels, and insulin resistance in obese patients with type 2 diabetes. Ann Intern Med. 2005 Mar 15;142(6):403-11. doi: 10.7326/0003-4819-142-6-200503150-00006.

Reference Type BACKGROUND
PMID: 15767618 (View on PubMed)

Shimazu T, Hirschey MD, Newman J, He W, Shirakawa K, Le Moan N, Grueter CA, Lim H, Saunders LR, Stevens RD, Newgard CB, Farese RV Jr, de Cabo R, Ulrich S, Akassoglou K, Verdin E. Suppression of oxidative stress by beta-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science. 2013 Jan 11;339(6116):211-4. doi: 10.1126/science.1227166. Epub 2012 Dec 6.

Reference Type BACKGROUND
PMID: 23223453 (View on PubMed)

Anderson JC. Measuring breath acetone for monitoring fat loss: Review. Obesity (Silver Spring). 2015 Dec;23(12):2327-34. doi: 10.1002/oby.21242. Epub 2015 Nov 2.

Reference Type BACKGROUND
PMID: 26524104 (View on PubMed)

Musa-Veloso K, Likhodii SS, Cunnane SC. Breath acetone is a reliable indicator of ketosis in adults consuming ketogenic meals. Am J Clin Nutr. 2002 Jul;76(1):65-70. doi: 10.1093/ajcn/76.1.65.

Reference Type BACKGROUND
PMID: 12081817 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RO-0001

Identifier Type: -

Identifier Source: org_study_id